<DOC>
	<DOCNO>NCT02392780</DOCNO>
	<brief_summary>Graft-versus-host-disease ( GVHD ) major obstacle successful allogeneic hematopoietic cell transplantation ( alloHCT ) . Cannabidiol ( CBD ) , non-psychotropic ingredient Cannabis sativa posse potent anti-inflammatory immunosuppressive property . In recent phase 2 study , CBD show safe reduce significantly incidence acute GVHD compare control patient hazard ratio 0.3 . Based result investigator propose phase 2 study explore efficacy oral CBD treatment severe ( grades III/IV ) acute GVHD , pathology dismal prognosis .</brief_summary>
	<brief_title>Cannabidiol Treatment Severe ( Grades III/IV ) Acute Graft-versus-host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients 18 year old 2 . After allogeneic transplantation 3 . Grade III IV acute GVHD 4 . No psychiatric contraindication 5 . Informed consent 1 . History psychosis 2 . Asthma 3 . Known allergy cannabis constituent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>